BPC-157 is one of the most extensively studied peptides in preclinical tissue repair research, with published data spanning tendon, muscle, bone, gastrointestinal, and neurological healing models
Most recently, we added VRB-101 for Obesity, VRB-101 for Obesity and Ponsegromab for Pancreatic Cancer to the Power online platform.
For glycemic control, a published comment concluded that tirzepatide microdosing at 2.5 mg resulted in a 15% reduction in HbA1c levels, indicating metabolic improvement even at modest exposures, as noted in a comment by Kom et al
Table of Contents Toggle BPC-157 in Maryland BPC-157, or Body Protection Compound-157 , is a synthetic peptide derived from a fragment of a naturally occurring protein in human gastric juice
A 72-week double-blind, placebo-controlled, delayed-start trial of rasagiline 1 mg or 2 mg in PD reported a reduction in motor progression as measured by the UPDRS score in the 1 mg group versus placebo, but the 2 mg group did not meet any prespecified endpoints [202]
)
